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Introduction intestine, no abnormalities were found, After washout
of the peritoneal cavity an infracolic omentectomy and 
Granulosa cell tumors comprise 3% to 10% of all total hysterectomy was performed with bilateral sal- 
malignant ovarian tumors. They are diagnosed at all pingo-oophorectomy including the adhesent part of the 
ages, but usually occur after the menopause [1]. The small intestine. Histological examination showed a 
most common presenting symptom is abnormal uterine granulosa-cell tumor of the right ovary confined within 
bleeding due to hormonal activity of the tumor. Com- the capsule (FIGO stage IA) and a carcinoma in situ of 
plete surgical removal is the management of choice for the endometrium of the uterus. The patient’s post-
operative recovery was uneventful and her serum beta- 
estradiol level returned to normal postmenopausal 
levels*
During follow-up the patient complained of disabl-
these tumors. The stage at the initial operation appears 
to be the most important prognostic factor for cancer- 
related survival. The management of metastatic disease 
or inoperable loco-regional relapse has yet to be de-
fined for this uncommon ovarian tumor The following ing flushes which were treated successfully with con- 
case history illustrates a number of management prob- jugated estrogen 1.25 mg daily.
lems in a patient with granulosa cell tumor of the ovary. 
Therapeutic options for the different stages of the dis­
ease will be discussed.
After two years the patient again experienced ab­
dominal pain. On examination no tumor was found but 
ultra-sonography revealed an abdominal mass. Deter­
mination of her estradiol levels was not helpful due to 
the estrogen medication. Laparotomy was performed 
and in addition to extensive adhesions, two peritoneal 
lesions of 1.0 and 4.0 cm diameter were found. Both 
A 59-year-old woman presented with a history of ab- lesions proved to be granulosa cell tumor and could be
Case history
dominal discomfort and dysuria of six months’ dura­
tion, with additional symptoms of dyspareunia and anal 
tenesmus. There was no history of vaginal discharge or
completely resected. No adjuvant therapy was given.
Six months later a routinely performed CT scan of 
the abdomen showed a local recurrence and liver
function tests all showed normal results apart from an 
elevated lactate dehydrogenase of 369 U/L (normal ^
bleeding. She was multiparous and had been post- metastases. The endogenous 17-beta-estradiol level
menopausal for eight years. On examination the only (after cessation of the estrogen medication) was elcvat-
abnormal finding was a mobile mass in her lower ab- ed to 180 pmol/L. Palliative poly-chemotherapy was
domen. Laboratory investigations including full blood started with PVB courses; cisplatin (20 mg/m2 day
count, plasma electrolytes, serum creatinine and liver 1-5), vinblastine (015 mg/kg days 1 and 2) and bleo­
mycin (30 mg/24-hour infusion on day 2 and 15 mg 
short infusion day 15) every four weeks. After two
250) and 17-beta-estradiol of 250 pmol/L (postmeno- courses there was a reduction in tumor size. After four
pausal woman normal <60). A  cervical smear showed courses early signs of bleomycin lung toxicity were
no abnormalities except for an absence of atrophy of detected on the chest X-ray and bleomycin was discon-
epithelial cells. The chest X-ray picture was normal, tinned. After six courses the patient developed poly-
Intravenous pyelography showed an impression on the neuropathy and chemotherapy was stopped. A partial
bladder but no urethral obstruction and ultra-sound response was obtained with normalization of estradiol
confirmed a solid mass originating in the right ovary. levels and elevation of luteinizing hormone (LH), fol~
An exploratory laparotomy was performed. Apart licle-stimulating hormone (FSH) levels to postmeno-
from adhesions of the enlarged right ovary to the small pausal values.
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One and a half years later, four years after the initial hormonal activity; they account for 70% of all feminiz-
presentation, abdominal pains recurred due to growth 
of the liver métastasés. Elevation of her serum estradiol
ing ovarian tumors. Precocity in young girls, estrogen 
stimulated vaginal smears and cervical mucus or endo-
levels (156 pm ol/L) had preceded clinical manifest a- metrial hyperplasia may alert the gynaecologist to the
tions four months earlier. Chemotherapy was re-insti­
tuted with carboplatin (day 1, 340 mg adjusted to 
creatinine clearance of 50 ml/min) and etoposide (120 
m g/m 2 days 1 -3) every three weeks. Again a partial 
response was seen after four courses, with normaliza­
tion of estradiol to postmenopausal levels. No further 
tumor regression could be achieved and treatment was 
stopped after the sixth course. The response lasted only 
six months. A  third attempt with polychemotherapy 
(carboplatin and etoposide) was less successful and 
stabilization of the tum or was the best response 
achieved with a total dose of six courses.
possible existence of a granulosa cell tumor. Labora­
tory tests may show an elevated estrogen level and low 
FSH and LH levels in menopausal women, but one- 
third of these tumors are not steroid-producing and 
investigations will be hampered by premenopausal sta­
tus or the use of exogenous estrogens. Inhibin, a poly­
peptide produced by granulosa cells, is stimulated by 
FSH and itself inhibits the release of FSH from the 
pituitary gland. Elevated levels of inhibin may also act 
as a marker for this tumor [7], but not specifically, as 
other ovarian cancers may also be associated with 
elevated levels of inhibin [8]. Histology is therefore
No further treatment was given and slow progres- necessary to prove the nature of the tumor. Thecomas
sion of the tumor advanced to end-stage disease one must be differentiated from granulosa cell tumors and
year later. A t that time the patient was completely bed- mixed granulosa-theca cell tumors. Pure thecomas are
ridden, complained of abdominal pain, loss of appetite, benign tumors of stromal origin, and only rarely do
night-sweats and tumor-related fever. The enlarged they recur after complete surgical removal [5]. Mixed
liver extended into the pelvis and the patient became tumors and pure granulesa-cell tumors are both malig-
dependent on blood transfusions at 10-day intervals, nant and have the same, less favourable prognosis. The
Palliative therapy with dexamethasone orally 3 mg tumors may show different histological patterns, but
daily was started, with considerable benefit. H er sub- the pattern does not correlate with survival [9].
jective symptoms disappeared and the massive liver Advanced clinical stage (FIGO II-IV), presence of
Discussion points
L Presenting sym ptom s> diagnosis and prognosis o f  
granulosa-cell ovarian tum or
mass shrank to only a small palpable rim just below the tumor rupture, large tumor (>5 cm) and high number 
right costal margin. The patient became transfusion- of mitotic figures are all associated with poor prognosis 
independent and was able to resume her normal daily [4-6, 9, 10]. The majority of patients (78%-92%) pre­
activities. This unexpected objective response on dexa- sent with FIGO stage I with five-year survival rates of 
methasone lasted for one year. Fifteen months later, 92% -98%  and at 10 years of 86% -92% . The five-year 
eight years after her initial diagnosis, the patient died of survival of FIG O  stage II is reported to be 57%-76%, 
progressive disease. and at 10 years 30% -61% . Survival in FIGO stages III
and IV at 5 and 10 years is 11%—22% and 6%, respec­
tively, but the total num ber of patients with advanced 
disease is very low in most series. The overall survival 
with granulosa cell tumor is more favourable than with 
epithelial cell cancer of the ovary. This may be at least 
partially due to the earlier stage at diagnosis of granu­
losa cell cancer, as stage for stage survivals are com- 
A minority of granulosa cell stromal tumors occur in parable for the two tumor types. Tumor relapses occur 
children before their fifth year and may present with on an average six years after initial diagnosis, but late 
sexual pseudo-precocity. The majority of the tumors recurrences of more than 20 years have been reported 
occur after the menopause (55%) or during reproduc- [2|. 
live life (40%) [2], A higher incidence has been report­
ed after ovarian stimulation with clomiphene citrate 2. Initial m anagem ent according to FIGO stage o f  
and/or gonadotrophins in patients with primary and granulosa-cell tum or o f  the ovary 
secondary infertility [3]. A bnorm al uterine bleeding
due to hormonal activity of the tumor is a presenting The initial treatment for granulosa-cell tumor of the 
symptom in more than one-half of the adult victims, ovary should be a bilateral oophorectomy with hyster- 
The endometrium may show cystic hyperplasia (60%) ectomy and removal of as much metastatic disease as 
and adenocarcinoma is reported in 3% to 13% of cases possible. Incomplete surgical removal is associated 
[4, 5], Abdominal discomfort and distension is noted in with a poorer overall prognosis [5,11, 12|.
one-third of the patients, of whom 8% may present There is no general consensus concerning the ad-
with acute symptoms due to torsion or rupture of the visability of a conservative unilateral oophorectomy in 
ovarian tumor [4, 6]. Virilization is a rare complication younger patients with limited disease and a strong wish
of androgen production by the tumor. for preservation of fertility. The available retrospective
Granulosa-cell tumors are diagnosed at an early studies are inconclusive. Conservative surgery was 
stage more often than other ovarian tumors due to their acceptable to Malkasian [2 ] only for patients with
FIGO stage IA disease. In contrast, Kietlinska [11] has follow-up lasting 6 -3 6  months no signs of relapse have 
pointed out that although the five-year survival in stage been noted. In addition to this small study, only anec- 
I disease is not compromised by conservative surgery, dotal reports of adjuvant chemotherapy have been pre- 
longer follow-up revealed that it carries a much less sented in the literature [14, 15|. Chemotherapy seems 
favourable prognosis than the one following radical to be indicated for patients with FIGO stage IC—III 
surgery. Conservative surgery must also deal with the tumors after surgical debulking, but the exact role of 
possibility of associated endometrial cancer and the adjuvant chemotherapy in the management of granu- 
occasional bilateral occurrence of the tumor. Although losa cell tumor of the ovary remains speculative, 
bilateral tumors are uncommon, with a reported inci­
dence usually of 2% -5%  of cases [4-6, 9], a much 4 , Follow-up after inilL 
higher incidence was noted by Ohel (26%) [10]. Unilat-
i-cell
tumor He ovary
eral oophorectomy should be preceded by dilatation
and curettage of the uterus, and biopsy of the remain- Because of the possibility of late recurrence even more
ing ovary has been advocated.
Radical surgery is therefore probably preferable in 
terms of overall prognosis, and the loss of child-bearing 
potential must be weighed carefully against the in­
creased chance of an incurable relapse after conserva­
tive surgery. Initial-presentation FIGO stage IV is very
than twenty years after initial treatment, follow-up for 
granulosa tumor of the ovary should be life-long [2 , 11).
History, physical examination and biochemical 
markers will be included in the follow-up examination. 
Serum estradiol levels may be a marker in those pa­
tients in whom elevated levels were found before initial
rare for granulosa-cell tumor and experience with man- therapy. Serum inhibin, although not specific for granu-
agement is sparse. The role of primary or secondary losa-cell cancer alone [8], may be an alternative and
debulking in these patients is unclear. Palliative chemo- sensitive marker for primary as well as recurrent dis-
therapy with cisplatin containing regimens may be ease and is less hampered by endogenous or exogenous
advisable [13]. estrogen. Elevation of the markers may precede clinical 
manifestations of recurrent disease by as long as 20
3. Adjuvant therapy in the management o f  granulosa- months [7],
cell tum or o f  the ovary The role of routine radiological diagnosis is not
clear. Recurrence may occur intra-abdominally as in 
The majority of patients present with FIGO stage IA or epithelial ovarian cancer. The first sites of metastases 
IB disease, and surgery alone will be adequate primary outside the peritoneal cavity are lungs, liver and even 
therapy. Local recurrence and metastases occur espe- the brain, spread hematogenously. Although there are 
daily in the higher stages. Compared with epithelial many recurrences within the first five years after initial 
cancer of the ovary the role of adjuvant therapy in therapy, the median interval is six years. The best ap- 
granulosa cell tumor FIGO stage IC and higher is less 
well understood. Prospective randomized studies are 
impracticable because of the low incidence of the 
tumor and the long interval during which relapses may 
occur. Results of treatment are derived from small non-
proach is to perform radiological investigation in 
patients in whom there is suspicion of relapse, based 
on the symptoms, physical examination or laboratory
results.
In addition to associated endometrial cancer, there 
randomized studies with short follow-up often not per- is evidence of an increased incidence of breast cancer
milting meaningful conclusions. in patients with granulosa-cell tumor of the ovary [2 ,
Many retrospective series report the use of adjuvant 10|. Incidences of 3.7% to 20% have been reported.
Periodic examination of the breasts and mammography 
have been advocated.
radiotherapy. Adjuvant radiotherapy seemed to be 
associated with a better prognosis after long-term fol­
low-up in the study of Kietlinska [11]. However, existing
data are too incomplete for meaningful comparison of 5. Management o f  inoperable advanced or relapsed
survival by stage of disease or other important prog­
nostic factors. Retrospective analysis by Evans [5], 
Ohe! [10] and Stenwig [4] did not document a possible 
positive effect of radiotherapy. At present there are no 
firm scientific arguments for adjuvant radiotherapy.
Colombo presented the results of cisplatin-contain- 
ing polychemotherapy in 11 patients with advanced or 
recurrent disease [13]. In six patients (four with FIGO 
stage III and two with stage IV) adjuvant therapy was 
given after primary surgical debulking. In all five pa­
tients in whom surgery had been optimal, a surgically 
verified complete remission was subsequently ob­
tained, while a patient who had sub-optimal surgery 
showed progression during polychemotherapy. During
granulosa-cell tum or o f  the ovary
There is no consistently effective management in ad­
vanced or relapsed granulosa cell cancer of the ovary 
Published experience with these patients is anecdotal. 
Although no cure is achieved, there have been reports 
of complete responses of long duration achieved by 
surgery, radiotherapy and chemotherapy, both alone 
and in combination.
Repeated surgical removal after recurrence has been 
reported to be successful in limited disease. Combina­
tion therapy of surgical debulking and radiotherapy or 
radiotherapy alone has been used [4, 5, 11 , 1.2, 16]. The 
combination of surgery and radiotherapy was superior
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in the opinion of Kietlinska [1.1], but comparative data References
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Chemotherapy has been used in patients with large 
residual disease, metastases and inoperable recur­
rences. A  twenty to twenty-five percent objective re­
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patients on monotherapy with melphalan and cyclo­
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been published [14, 17, 18]. Combination chemother­
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chemotherapy and longer-lasting responses. Until now 10- 
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therapy or the num ber of courses to be given. M ore­
over, nothing is known of the possible activity of newer 12. 
drugs such as taxol in granulosa cell tumor of the ovary.
In this case history an unexpected response oc­
curred on dexamethasone. Until now no such response 
has been reported in the literature. Clarification of the 
implications of this observation await publication of the 14. 
experiences of others.
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17.
Many questions about the management of granulosa- 
cell tumor of the ovary remain unanswered. Its low 
incidence and long relapse interval preclude a rapid 
comprehension of the biology of the tumor and defini- \#m 
tion of the best treatment option in advanced or meta­
static disease. The cornerstone of treatment remains
19.
20.
surgery. In all studies patients with early-stage disease 
and optimal debulking proved to have the best prog­
noses even in recurrent disease. Patients with stage IC 
disease or worse may benefit from adjuvant therapy 
especially after optimal surgery, but there have been no 
well-designed studies to determine the role of radio­
therapy or chemotherapy. Theoretically chemotherapy
has the advantage of treating distant metastases as well, Correspondence to: 
which do occur in granulosa cell tumors. Recurrent dis­
ease may respond to radiotherapy or chemotherapy, 
but the best results have been obtained after optimal 
surgery. Nevertheless individual patients may benefit 
from one treatment modality subsequent to the other 
after a long period has elapsed.
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